Ruxolitinib, bizwi kandi nka ruxolitinib mu Bushinwa, ni umwe mu "miti mishya" yashyizwe ku rutonde rw’ubuvuzi bwo kuvura indwara z’amaraso mu myaka yashize, kandi ikaba yerekanye ingaruka nziza mu ndwara ziterwa na myeloproliferative.
Ibiyobyabwenge byibasiwe na Jakavi ruxolitinib birashobora guhagarika neza imikorere yumurongo wose wa JAK-STAT no kugabanya ibimenyetso byongerewe bidasanzwe byumuyoboro, bityo bikagera kubikorwa.Irashobora kandi gukoreshwa mukuvura indwara zitandukanye, no kurubuga rwa JAK1 rudasanzwe.
Ruxolitinibni inzitizi ya kinase yerekanwe kuvura abarwayi bafite myelofibrosis hagati cyangwa ibyago byinshi, harimo myelofibrosis primaire, post-geniculocytose myelofibrosis, na trombocythemia myelofibrosis.
Ubushakashatsi busa nubuvuzi (n = 219) bwatoranije abarwayi bafite ibyago byo hagati-2 cyangwa ibyago byibanze bya MF, abarwayi bafite MF nyuma ya erythroblastose nyayo, cyangwa abarwayi bafite MF nyuma ya trombocytose yibanze mumatsinda abiri, umwe yakira ruxolitinib umunwa 15 kugeza 20 mgbid. (n = 146) undi yakira imiti igenzura neza (n = 73).Icyiciro cyibanze ningenzi byingenzi byanyuma byubushakashatsi ni ijanisha ryabarwayi bafite ≥35% kugabanuka kwijwi ryayo (bisuzumwa na magnetic resonance imaging cyangwa computing tomografiya) mubyumweru 48 na 24.Ibisubizo byagaragaje ko ijanisha ry’abarwayi bafite igabanuka rirenga 35% ry’ubunini bw’intanga kuva ku cyumweru cya 24 byari 31.9% mu itsinda ry’ubuvuzi ugereranije na 0% mu itsinda rishinzwe kugenzura (P <0.0001);n'ijanisha ry'abarwayi bafite igabanuka rirenga 35% ry'ubunini bw'intanga kuva ku cyumweru cya 48 byari 28.5% mu itsinda ryo kuvura ugereranije na 0% mu itsinda rishinzwe kugenzura (P <0.0001).Byongeye kandi, ruxolitinib nayo yagabanije ibimenyetso muri rusange kandi yazamuye ubuzima bwiza kubarwayi.Ukurikije ibisubizo by'ibi bigeragezo byombi,ruxolitinibibaye imiti yambere yemejwe na FDA yo muri Amerika kuvura abarwayi bafite MF.